Next Article in Journal
The Evanescent GacS Signal
Next Article in Special Issue
Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus
Previous Article in Journal
Intestinal Barrier Function in Health and Disease—Any Role of SARS-CoV-2?
Previous Article in Special Issue
TRIM Proteins and Their Roles in the Influenza Virus Life Cycle
Open AccessReview

New Technologies for Influenza Vaccines

1
Technical Development, Seqirus Ltd, Parkville, Victoria 3052, Australia
2
Department of Immunology and Microbiology, The University of Melbourne, Parkville, Victoria 3052, Australia
3
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, The Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(11), 1745; https://doi.org/10.3390/microorganisms8111745
Received: 9 October 2020 / Revised: 4 November 2020 / Accepted: 4 November 2020 / Published: 6 November 2020
(This article belongs to the Special Issue The Biology of Influenza Viruses)
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine. View Full-Text
Keywords: influenza; vaccine; universal vaccine; cell-culture; egg-based influenza vaccines; cell-based influenza vaccines; recombinant vaccines; mRNA vaccines influenza; vaccine; universal vaccine; cell-culture; egg-based influenza vaccines; cell-based influenza vaccines; recombinant vaccines; mRNA vaccines
Show Figures

Figure 1

MDPI and ACS Style

Rockman, S.; Laurie, K.L.; Parkes, S.; Wheatley, A.; Barr, I.G. New Technologies for Influenza Vaccines. Microorganisms 2020, 8, 1745. https://doi.org/10.3390/microorganisms8111745

AMA Style

Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New Technologies for Influenza Vaccines. Microorganisms. 2020; 8(11):1745. https://doi.org/10.3390/microorganisms8111745

Chicago/Turabian Style

Rockman, Steven; Laurie, Karen L.; Parkes, Simone; Wheatley, Adam; Barr, Ian G. 2020. "New Technologies for Influenza Vaccines" Microorganisms 8, no. 11: 1745. https://doi.org/10.3390/microorganisms8111745

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop